Literature DB >> 19734424

The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.

Gabriella Sozzi1, Maria Paola Martelli, Davide Conte, Piergiorgio Modena, Valentina Pettirossi, Stefano A Pileri, Brunangelo Falini.   

Abstract

Rearrangements involving the ALK gene define two distinct entities in the new 2008 WHO classification of lymphoid neoplasms, i.e. ALK+ anaplastic large cell lymphoma and a rare subset of ALK+ diffuse large B-cell lymphoma. Recently, rearrangements involving ALK and the echinoderm microtubule associated protein-like 4 (EML4) gene were described as a specific genetic alteration in about 6% of non-small cell lung cancer (NSCLC). We investigated the expression of EML4-ALK mRNA and protein in 51 reactive and 58 neoplastic lymphoid tissues. EML4-ALK transcripts were detected in 3/51 (5.9%) of reactive lymphoid tissues and 12/58 (20.7%) of lymphomas of different categories, including follicular lymphoma, diffuse large B-cell lymphoma and Hodgkin's disease. Notably, none of these cases expressed the EML4-ALK fusion protein at Western blotting samples and immunohistochemistry. These results indicate that EML4-ALK rearrangements are not specific of NSCLC and raise yet unsolved questions about their role in promoting human neoplasms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734424      PMCID: PMC2738726          DOI: 10.3324/haematol.2009.008045

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Authors:  B Falini; B Bigerna; M Fizzotti; K Pulford; S A Pileri; G Delsol; A Carbone; M Paulli; U Magrini; F Menestrina; R Giardini; S Pilotti; A Mezzelani; B Ugolini; M Billi; A Pucciarini; R Pacini; P G Pelicci; L Flenghi
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

2.  Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.

Authors:  K Pulford; B Falini; J Cordell; A Rosenwald; G Ott; H K Müller-Hermelink; K A MacLennan; L Lamant; A Carbone; E Campo; D Y Mason
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

3.  ALK+ lymphoma: clinico-pathological findings and outcome.

Authors:  B Falini; S Pileri; P L Zinzani; A Carbone; V Zagonel; C Wolf-Peeters; G Verhoef; F Menestrina; G Todeschini; M Paulli; M Lazzarino; R Giardini; A Aiello; H D Foss; I Araujo; M Fizzotti; P G Pelicci; L Flenghi; M F Martelli; A Santucci
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

Review 4.  ALK-positive lymphoma: a single disease with a broad spectrum of morphology.

Authors:  D Benharroch; Z Meguerian-Bedoyan; L Lamant; C Amin; L Brugières; M J Terrier-Lacombe; E Haralambieva; K Pulford; S Pileri; S W Morris; D Y Mason; G Delsol
Journal:  Blood       Date:  1998-03-15       Impact factor: 22.113

5.  Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations.

Authors:  M Beylot-Barry; A Groppi; B Vergier; K Pulford; J P Merlio
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

6.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

7.  Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Authors:  Kengo Takeuchi; Young Lim Choi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

8.  Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?

Authors:  K Orscheschek; H Merz; J Hell; T Binder; H Bartels; A C Feller
Journal:  Lancet       Date:  1995-01-14       Impact factor: 79.321

9.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  3 in total

1.  A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Authors:  Mari Mino-Kenudson; Lucian R Chirieac; Kenny Law; Jason L Hornick; Neal Lindeman; Eugene J Mark; David W Cohen; Bruce E Johnson; Pasi A Jänne; A John Iafrate; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  EML4-ALK fusion in lung.

Authors:  Hiroyuki Mano; Kengo Takeuchi
Journal:  Am J Pathol       Date:  2010-01-14       Impact factor: 4.307

3.  Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.

Authors:  Difan Zheng; Rui Wang; Yang Zhang; Yunjian Pan; Xinghua Cheng; Chao Cheng; Shanbo Zheng; Hang Li; Ranxia Gong; Yuan Li; Xuxia Shen; Yihua Sun; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-08       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.